MARKET

FENC

FENC

Fennec Pharmaceuticals Inc
NASDAQ
13.70
+0.37
+2.74%
Opening 14:30 11/19 EST
OPEN
13.40
PREV CLOSE
13.33
HIGH
13.84
LOW
13.20
VOLUME
299.60K
TURNOVER
--
52 WEEK HIGH
13.85
52 WEEK LOW
5.65
MARKET CAP
480.24M
P/E (TTM)
485.64
1D
5D
1M
3M
1Y
5Y
1D
Fennec Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
Fennec Pharmaceuticals Price Target Raised to $17.00/Share From $16.00 by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $17
Benzinga · 1d ago
Fennec price target raised to $17 from $16 at H.C. Wainwright
TipRanks · 1d ago
H World Group Posts Upbeat Q3 Earnings, Joins CG Oncology, TELUS And Other Big Stocks Moving Higher On Monday
Benzinga · 3d ago
Fennec Pharmaceuticals Price Target Raised to $19.00/Share From $18.00 by B. Riley Securities
Dow Jones · 3d ago
B. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $19
Benzinga · 3d ago
Fennec price target raised to $19 from $18 at B. Riley
TipRanks · 3d ago
More
About FENC
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

Webull offers Fennec Pharmaceuticals Inc stock information, including NASDAQ: FENC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FENC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FENC stock methods without spending real money on the virtual paper trading platform.